206
Participants
Start Date
August 21, 2023
Primary Completion Date
October 9, 2024
Study Completion Date
October 9, 2024
Tirzepatide
Administered SC
Placebo
Administered SC
Chinese PLA General Hospital, Beijing
Dalian University - The Affiliated Zhongshan Hospital, Dalian
Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian
Panjin Liaoyou Baoshihua Hospital, Liaoyou
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
Pudong New Area People's Hospital Shanghai, Shanghai
Jiading District Central Hospital, Shanghai
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
Nanjing First Hospital, Nanjing
Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing
Affiliated Hospital of Jiangsu University, Zhenjiang
The First Affiliated Hospital of Soochow University, Suzhou
Jinan Central Hospital, Jinan
Tianjin Medical University General Hospital, Tianjin
Huzhou Central Hospital, Huzhou
Jiangxi Pingxiang People's Hospital, Pingxiang
The First People's Hospital of Changde City, Changde
Yichang Central People's Hospital, Yichang
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi
The First Affiliated Hospital of Nanyang Medical College, Nanyang
Huizhou Municipal Central Hospital, Huizhou
Shunde Hospital of Southern Medical Univesity, Foshan
Zunyi First People's Hospital, Zunyi
Hainan General Hospital, Haikou
West China Hospital of Sichuan University, Chengdu
Chengdu Fifth People's Hospital, Chengdu
The First Affiliated Hospital of Xi'an Medical University, Xi'an
Eli Lilly and Company
INDUSTRY